DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Musculoskeletal Disorders Therapeutics Market 2016-2020" report to their offering.
About Musculoskeletal Disorders
The global musculoskeletal disorder therapeutics market to grow at a CAGR of 4.46% during the period 2016-2020.
The report covers the present scenario and the growth prospects of the global musculoskeletal disorder therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used to treat musculoskeletal disorders including osteoarthritis, rheumatoid arthritis, osteoporosis, ankylosing spondylitis, psoriatic arthritis, and fibromyalgia.
Musculoskeletal disorders are the group of pain disorders or injuries that affect the body's joints, muscles, nerves, ligaments, tendons, and structures, all of which support the hands, legs, neck and back. The pain and discomfort vary with the severity of the condition. These disorders have a wide range of causes, but usually occur depending on the age, lifestyle, and occupation of an individual. Symptoms usually range from recurrent pain, stiffness, and swellings. X-rays and other medical imaging procedures may diagnose the condition. The treatment mainly depends on the severity of the condition. Apart from the drugs, physical therapy, and occupational therapy are also used to manage the condition.
- Johnson & Johnson
- F. Hoffmann-La Roche
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Pipeline portfolio
Part 06: Market landscape
Part 07: Market segmentation by disease type
Part 08: Global rheumatoid arthritis drugs market
Part 09: Global osteoarthritis drugs market
Part 10: Global osteoporosis drugs market
Part 11: Global ankylosing spondylitis drugs market
Part 12: Global psoriatic arthritis drugs market
Part 13: Global fibromyalgia drugs market
Part 14: Market segmentation by type of molecule
Part 15: Market segmentation by route of administration
Part 16: Geographical segmentation
Part 17: Market drivers
Part 18: Impact of drivers
Part 19: Market challenges
Part 20: Impact of drivers and challenges
Part 21: Market trends
Part 22: Vendor landscape
Part 23: Key vendor analysis
For more information about this report visit http://www.researchandmarkets.com/research/rrzztj/global
Related Topics: Musculoskeletal Disorders Drugs